Shots:

• The P-III (CHAMPION-NMOSD) trial evaluating Ultomiris vs PBO in 58 adult patients with NMOSD across North America, the EU, Asia-Pacific, and Japan. Patients who completed the primary treatment period were eligible to participate in the ongoing LTE period
• The results showed a 98.6% reduction in risk of relapse with dosing q8w in adults with AQP4 Ab+ NMOSD, zero relapses with a median treatment duration of 73wks., 100% vs 63% remained relapse-free @48wks.
• The trial also met key secondary efficacy EPs incl. adjudicated on-trial annualized relapse rate & change from baseline in mobility (ability to walk) & the safety and tolerability were consistent with prior studies and real-world use & no new safety signals were seen. The company also highlighted the results in two posters from subgroup and sensitivity analyses

Ref: AstraZeneca  | Image: AstraZeneca